The objective of this study was to compare the effects of risperidone and olanzapine in schizophrenic patients with intolerant extrapyramidal side effects (EPS) on first generation antipsychotics. We conducted an 8-week, rater-blinded, flexible dose study. Seventy patients with schizophrenia, who met the DSM-IV research criteria of having neuroleptic-induced acute dystonia or parkinsonism, were randomly assigned to risperidone or olanzapine group. The primary outcome was a comparison of the incidence of concomitant anticholinergic drugs usage between the groups to manage their acute dystonia and parkinsonism. The average doses of risperidone and olanzapine from baseline to study end point were 1.8-3.5 mg/day and 7.7-11.7 mg/day, respectively. There were no significant differences in demographic data, severity of EPS or psychotic symptoms between the groups at baseline assessment. Patients taking risperidone had significantly higher incidence of using anticholinergic drugs to manage acute dystonia or parkinsonism overall during the study (OR = 5.17, 95%CI = 1.49-17.88, P = 0.013). There was no significant between-group difference in the changing of rating scales of EPS and psychotic symptoms. The results of our study favour olanzapine as a better choice in schizophrenic patients with intolerant EPS. Double-blinded, fixed dose and different ethnical study for EPS-intolerant schizophrenic patients is needed to confirm the results of our study.
Introduction
Many patients with schizophrenia experience extrapyramidal side effects (EPS) after the use of first-generation antipsychotics (FGA). The incidences might be up to 60-70% (Casey, 1991; Grohmann, et al., 1990) . Acute dystonia, akathisia and parkinsonism may predict subsequent development of tardive dyskinesia (TD) (Correll, et al., 2004; Sachdev, 2004) , and the prevalence of these EPS coexisting with TD is nearly 30% (Richardson and Craig, 1982) . Furthermore, acute dystonia, akathisia and parkinsonism would impair patient's drug compliance, which may lead to relapse and re-hospitalisation (Weiden and Miller, 2001; Leucht, et al., 2003) .
Second-generation antipsychotics (SGA) have a lower EPS incidence, greater efficacy for negative symptoms and cognitive function, better drug compliance and a lower relapse rate than FGA (Glazer, 2000; Sharma and Antonova, 2003; Awad and Voruganti, 2004; Dossenbach, et al., 2005) . Although SGA have some advantages in treating patients with schizophrenia, many countries cannot use them as first-line medications because of their higher price (Emsley, et al., 1999) . The National Health Insurance Bureau of Taiwan had restrictive regulations governing the use of SGA before 2003. In recent years, regulations regarding the use of SGA have become looser, but many psychiatrists in Taiwan still need to use FGA as first-line medications because of budget limitations for hospitals.
Different SGA involve different pharmacological mechanisms (Huttunen, 1995; Lane, et al., 1988; Seeman and Tallerico, 1998) , but which one is the best choice for a population with high EPS on FGA is still unknown. Only a few studies of SGA have focused on EPS-intolerant patients. Heck, et al. (2000) study showed that risperidone and haloperidol did not have significant difference in total scores of parkinsonism, but the mean dose of risperidone in this study was too high, up to 7.4 mg/day. Costa e Silva, et al. (2001) study showed that olanzapine could significantly improve EPS and psychotic symptoms. However, this study was only an observational study. To our knowledge, there are no head-to-head comparison studies with different SGA in patients who cannot tolerate the EPS of FGA.
Risperidone and olanzapine might have different EPS severity, efficacy on psychotic symptoms and other domains because of different receptor profiles. However, the data, including EPS severity, from head-to-head comparison studies of these two medications were contradictory (Tran, et al., 1997; Conley and Mahmoud, 2001 ). Our hypothesis is that these two medications have different EPS severity in an EPS-intolerant population. For the above reasons, we initiated a study to compare risperidone and olanzapine in Han-Chinese schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.
Materials and methods
This study was conducted at a public mental hospital in Taiwan from July 2000 to July 2003. It was conducted in accordance with the principles of the Helsinki Declaration and Good Clinical Practice. The study protocol was approved by the Ethics Committee of that hospital. All patients or those legally responsible for them gave informed written consent after the study procedure had been fully explained before their inclusion in this study. Details that might disclose the identity of patients under study were omitted.
Inclusion and exclusion criteria
Inclusion criteria included: aged 18-65; female patients who did not have plans to become pregnant and who agreed to use reliable contraception methods if at childbearing age; meeting the DSM-IV schizophrenia criteria; fulfilling DSM-IV neuroleptic-induced acute dystonia or parkinsonism research criteria, with a severity of acute dystonia or parkinsonism greater than moderate degree (>4) as assessed by the global impression of Extrapyramidal System Rating Scale (ESRS) (items 43 and 44 of the ESRS) (Chouinard and Margolese, 2005) ; and patients or legally responsible people agreeing to join the study and sign informed consent. Exclusion criteria included patients with other axis I diagnoses in the DSM-IV; unstable major systemic diseases; a history of neurological disorders that would influence the EPS assessment and substance abuse or dependence other than coffee or tobacco within 6 months before the study. All patients received a psychiatric evaluation to decide whether they met inclusion or exclusion criteria at the screening visit.
Clinical assessments
Brief Psychiatric Rating Scale (BPRS, 18 items, score: 1-7, range: 7-126) (Overall and Gorham, 1988) , Clinical Global Impression-Severity (CGI-S, range: 1-7) (Guy, 1976) , ESRS (subjective assessment, 7 items, score: 0-3, range: 0-21; parkinsonism and akathisia, 17 items, score: 0-6, range: 0-102; dystonia, 10 items, score: 0-6, range: 0-60; dyskinesia, 7 items, score: 0-6, range: 0-42; global impression, 4 items, score: 0-8 for each item) were used to assess the severity of psychotic symptoms and the severity of EPS. Two investigators (CHC & JJC) served as blind raters. They had video training for ESRS and performed inter-rater reliability through joint assessment of 10 patients with EPS before the study. The coefficiencies of agreement in subjective examination, parkinsonism and akathisia, dystonia, TD and global impression of ESRS were 0. 89, 0.83, 0.92, 0.84 and 0.75, respectively. 
Study design
Because anticholinergic drugs would influence the severity of EPS assessment, we compared the incidence of acute dystonia or parkinsonism that necessitated use of anticholinergic drugs between the risperidone and olanzapine groups as the primary outcome of this study. The secondary outcome was to compare the changes in scores of the different rating scales between the two groups.
Eligible patients fulfilling inclusion/exclusion criteria entered a washout period of 3-7 days before randomisation. Patients stopped using any antipsychotics, mood stabilisers, antidepressants and dopamine agonists during the washout period and throughout the entire study period. If the patients had received depot medications, the screening day would have been at least 1 injection cycle before the last injection. Anticholinergic drugs, propranolol and daytime benzodiazepine (BZD) were allowed during the washout period but were discontinued when the study period started. Global impression of ESRS were rated every 3-4 days after screening visit until the global severity of acute dystonia or parkinsonism not more than moderate severity (items 43 and 44 ≤ 4).
If patients reached the above criteria, they were then randomly assigned to receive either olanzapine or risperidone with a 1 to 1 ratio by coin method with a six-block design. The study period lasted 8 weeks. BPRS, CGI-S and ESRS, were performed at baseline, weeks 1, 2, 3, 4, 8 or the endpoint visit. Information on adverse events, body weight, vital signs, concomitant medications and the dosage of study medications were also recorded by the attending physicians.
Patients were judged to need anticholinergic drugs by the blind-raters after the randomisation phase. If they had acute dystonia or parkinsonism, and the severity was greater than the moderate degree of ESRS global impression (>4), the blind-raters make the decision that this patient needed anticholinergic drugs. The dose and class of anticholinergic drugs were determined by attending physicians according to patient's clinical condition. If they had not acute dystonia or parkinsonism, or they had acute dystonia or parkinsonism but the severity of acute dystonia or parkinsonism was no more than the moderate degree of ESRS global impression (≤4), the blind-raters would inform attending physicians that this patient should not have anticholinergic drugs. Propranolol and daytime BZD could be prescribed to treat akathisia. Intramuscular lorazepam not more than 8 mg/day was allowed if the patients had agitated or exhibited violent behaviour.
Dosing strategy
This study was a flexible dose design, with the dose range of risperidone and olanzapine at 0.5-6 mg/day and 2.5-20 mg/day, respectively. The dose range was determined by the suggested optimal dose for general schizophrenic patients in Taiwan (risperidone 2-6 mg/day, olanzapine 10-20 mg/day) (Liu, et al., 2003) . Considering that the EPSintolerant patients may need lower doses, we decided to use a dose range 1/4 lower than the dose range of general schizophrenic patients as the lower dose range of our study. The dose change depended on the clinical judgment of the nonblinded investigators. The amount of the patient's study medications were counted to ensure drug compliance. If the patient's medication use was below 80% or beyond 120%, this would be defined as a protocol deviation and required early termination.
Statistical methods
All patients who were randomly assigned and had at least one post-baseline assessment were included in the intent-to-treat (ITT) analysis. If the ITT subjects were early terminators, the last observation carried forward (LOCF) method was used to extend the endpoint scores. For the between-group comparison, chi-square or Fisher's exact test for the categorical data and independent t-test for continuous data was performed. The mixed model for repeated measurements was used for continuous variables with repeated measurements. If we considered the time of using anticholinergic drugs and the censored status of patients (censored cases means patients dropped out from study not because of EPS side effects), the Kaplan-Meier method and Cox regression were used to analyse survival data. All results are expressed as means and standard deviations. The level of significant difference is two-sided, P < 0.05. The data were analysed by SAS, Chinese version 9.1 (SAS Institute Inc., Cary, NC, USA).
Sample size calculation
The sample size calculation was performed according to our clinical experience that the incidences of concomitant anticholinergic drugs in EPS-intolerant patients were about 50% and 15% for risperidone and olanzapine, respectively. Under the condition of α = 0.025 two-sided and 80% power, we needed at least a total 44 patients. We assumed a 30-40% drop-out rate, thus, the sample size would be about 68 patients.
Results

Patient disposition and demographics
Ninety-four patients were screened and entered a 3-to 7-day washout period. Twenty-four patients were excluded before randomisation, for the following reasons: six patients did not have a schizophrenic disorder, four patients still had EPS >4 after washing period (7 days), two patients appeared psychotic symptoms worsening, 11 patients did not meet the other criteria and one patient withdrew consent. The remaining 70 patients were assigned by randomisation, with 35 patients in each group. All 70 patients received study medications and had at least one post-baseline assessment. Seven and six patients terminated early in the risperidone and olanzapine group, respectively. The participant flow chart and the reasons of early termination were shown in Figure 1 .
These 70 patients were all received anticholinergic drugs at screening visit for their severe EPS. There were no significant differences between the groups in age, sex, duration of illness of schizophrenia, duration of antipsychotics treatment, global impression of parkinsonism of ESRS, global impression of acute dystonia of ESRS and the chlorpromazine equivalent dose at the screening visit. The characteristics of these two patient groups at screening visit are summarised in Table 1 . In risperidone group, the previous FGAs before entering study were as follows: 10 patients with sulpiride, 5 patients with haloperidol, 4 patients with zotepine, pipotiazine and trifluoperazine, , 2 patients with flupenthixol, clopenthixol and thioridazine, 1 patient with chlorpromazine and loxapine. In olanzapine group, the previous FGAs were as follows: 11 patients with sulpiride, 7 patients with haloperidol, 4 patients with flupenthixol and clopenthixol, 3 patients with zotepine, 2 patients with pipotiazine, trifluoperazine and clotiapine. There were no significant differences between risperidone and olanzapine group in the frequency of previous FGAs.
Total scores of BPRS and CGI-S, total scores and global impression of parkinsonism of ESRS, total scores and global impression of acute dystonia of ESRS, global impression of akathisia of ESRS, and body weight at baseline showed no significant differences between the groups. The days between screening and baseline also showed no significant differences between the groups. The characteristics of these two patient groups at baseline are summarised in Table 2 . After washout period, ESRS global impression of parkinsonism decreased from 5.5 ± 0.7 to 3.5 ± 0.8 in risperidone group and from 5.2 ± 1.2 to 3.4 ± 0.7 in olanzapine group. ESRS global impression of dystonia decreased from 0.6 ± 1.2 to 0.1 ± 0.4 and from 1.3 ± 1.9 to 0.3 ± 0.9 in these two groups, respectively. The study population comprised chronic schizophrenic patients of 40 years old on average and with moderateto-severe psychotic symptoms. Sixty-seven patients were recruited into this study because of intolerance to parkinsonism side effects of FGA. The three remaining patients were because of acute dystonia.
Dose of study medications
The dosages of the two groups gradually increased from baseline to endpoint. The mean dose at baseline, 1st, 2nd, 3rd, 4th and 8th week was 1.79 ± 0.66, 2.36 ± 0.97, 2.85 ± 1.1, 2.98 ± 1.29, 3.21 ± 1.41 and 3.45 ± 1.54 mg/day for risperidone group and 7.71 ± 2.53, 9.21 ± 3.68, 10.98 ± 5.23, 11.44 ± 5.19, 11.33 ± 5.23 and 11.72 ± 4.87 mg/day for olanzapine group, respectively.
Incidence of concomitant medications
There were 18 patients receiving anticholinergic drugs during the study period. The overall incidence of concomitant anticholinergic drug usage to treat parkinsonism or acute dystonia was significantly higher in the risperidone group (14/35 vs 4/35, odds ratio = 5.17, 95% confidence interval: 1.49-17.88, P = 0.013). If we used survival analysis to deal with the event time of anticholinergic drug use and censored cases, risperidone Completers, n=29
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Figure 1 Participant flow chart. still had a higher hazard ratio (hazard ratio: 4.60, 95% CI: 1.70-11.52; log-rank test: P < 0.005, Figure 2 ). The risperidone group also had a significantly higher incidence of concomitant propranolol usage to treat akathisia during the overall study (6/29 vs 0/35, P < 0.05). However, the incidence of concomitant daytime BZD to treat akathisia showed no significant difference between the groups (7/28 vs 2/33, P = 0.15). Two patients needed to use i.m. lorazepam to manage agitated symptoms, with one case in each group.
EPS and psychotic symptoms rating scale assessments
The changes in all rating scale assessments, from baseline to endpoint visits, showed no significant differences between groups tested by independent t-test, and included total scores of parkinsonism and akathisia of ESRS, total scores of dystonia of ESRS, global impression of parkinsonism of ESRS, global impression of dystonia of ESRS, global impression of akathisia of ESRS, CGI-S and total scores of BPRS (Table 3) . Even we used a mixed model for repeated measurements to test the slope of the change of total scores of BPRS and other rating scales, there were still no difference between the groups. There were significant improvements in the change of total scores of BPRS (risperidone, P < 0.0001; olanzapine, P < 0.0001), CGI-S (risperidone, P < 0.0001; olanzapine, P < 0.0001) and total scores of parkinsonism (risperidone, P = 0.0032; olanzapine, P = 0.0003) from baseline to study endpoint in both groups tested by mixed model. Total scores of acute dystonia had significant improvement only in the olanzapine group (P = 0.047). Global impression of parkinsonism, acute dystonia and akathisia in both groups showed no significant improvement in either groups.
We made a subgroup analysis to examine the 18 patients who needed use of anticholinergic drugs. The EPS severity assessed by ESRS had significant increase from baseline to the date of anticholinergics initiation. The total scores of subjective assessment (3.34 ± 3.03, P = 0.0002), total scores of parkinsonism (10.22 ± 7.81, P < 0.0001), global impression of parkinsonism (2.17 ± 0.71, P < 0.0001), global impression of akathisia (1.28 ± 2.05, P = 0.017) all significantly increased compared with the ratings at baseline. EPS severity had significant decrease after the use of anticholinergic drugs. Total scores of subjective assessment (−6.06 ± 3.39, P < 0.0001), total scores of parkinsonism (−18.00 ± 9.65, P < 0.0001), global impression of parkinsonism (−2.11 ± 1.23, P < 0.0001), global impression of akathisia (−1.72 ± 1.87, P = 0.0011) all have significant difference from the initiation day of anticholinergics to study endpoint.
Other safety results
There were no significant between-group differences in side effects (Table 4 ). The most frequent side effects in both groups were body weight gain greater than 7%: 17.1% in the Test by independent t-test. CGI-S, Clinical Global Impression Severity of Illness Scale; BPRS, Brief Psychiatric Rating Scale; ESRS, Extrapyramidal Rating Scale. risperidone group and 25.7% in the olanzapine group. The other common side effects (>10%) in the risperidone group were headache, drowsiness, and weakness, and in the olanzapine group, drowsiness and weakness. The average body weight gain in the risperidone and olanzapine groups from baseline to endpoint was 1.17 ± 3.20 kg and 1.61 ± 3.10 kg, respectively, which showed no significant difference (P = 0.60). No severe adverse events appeared during the study period.
Discussion
To the best of our knowledge, this study is the first randomised controlled study to compare risperidone and olanzapine in patients with schizophrenia, who have severe neurolepticinduced acute dystonia or parkinsonism side effects on FGAs. This study may provide directions about drug choice for patients with EPS intolerance.
Our flexible dose design showed that the mean dose of risperidone and olanzapine was similar to that in general clinical practice. The mean dose of risperidone in our study was more optimal than that in the study of the Heck, et al. (2000) . Many treatment guidelines or papers suggest that risperidone exceeding 6 mg/day had higher incidence of EPS (Lehman, et al., 2004; Citrome and Volalka, 2002; Davis and Chen, 2004) . The mean dose of olanzapine in our study was similar to that in the study of Costa e Silva, et al. (2001) , with a mean dose of 11.4 mg/day. The dose used in our study was also similar to that of a study done in Israel, in which the researchers used a questionnaire to ask clinicians about the optimal dose for EPSsensitive schizophrenic patients; and the results obtained were 3.7 mg/day for risperidone and 11.8 mg/day for olanzapine (Robinowitz, et al., 2000) . This result might reflect the idea that EPS-intolerant patients use lower doses so as to alleviate EPS and effectively control psychotic symptoms.
If patient's condition was stable, we intended to washout longer periods until complete remission of patient's acute dystonia or parkinsonism and to discontinue all anti-EPS medications. In our study design, we did not wait until all subjects' EPS disappearing and allowed use of anti-EPS medications during washout period considering the risk of worsening Table 3 Between-group differences in changes in severity of EPS and psychotic symptoms from baseline to endpoint Test by independent t-test. CGI-S, Clinical Global Impression Severity of Illness Scale; BPRS, Brief Psychiatric Rating Scale; ESRS, Extrapyramidal Rating Scale. psychotic symptoms and decreasing patient's motivation to the study. As expected, two patients had psychotic symptoms worsening during washout period and cannot enter randomisation phase. We thus decided to use below or equal to moderate severity of acute dystonia or parkinsonism side effects as a tolerable situation to enter this study. We used concomitant anticholinergic drugs as the primary outcome measurement and the results showed that the risperidone had a higher incidence of clinically significant acute dystonia or parkinsonism necessitating use of anticholinergic drugs. The results of the ESRS rating scale used in assessing the severity of EPS showed no significant between-group differences. This contradictory result is very likely because of the fact that EPS severity may be influenced by the use of anti-EPS medications. As shown in the subgroup analysis of those 18 patients who used anticholinergic drugs, there are significant increase in EPS severity from baseline to the date of using anticholinergic drugs and significant improvement after the use of anticholinergic drugs. This result is compatible with our hypothesis that the ratings of EPS scales are not ideal end points to reflect the real difference of EPS liability of different antipsychotics under the influence of using anti-EPS medications.
The incidence of using anticholinergic drugs as concomitant medications in the risperidone group in our study was 40%, higher than the result obtained by Heck's, et al., which were 28%. The incidence of use in the olanzapine group was 11.43%, similar to that reported by Costa e Silva, et al., which was 12.8%. The risperidone dose used in our study was much lower than that used by Heck's, et al., but our results of concomitant anticholinergic drug use were higher. Two reasons could account for such difference. First, our patients were really very EPS sensitive. The average chlorpromazine equivalent dose at screening was below 380 mg/day, and severe acute dystonia or parkinsonism still occurred, even when original FGA was combined with anti-EPS medications. Therefore, the incidence of significant acute dystonia or parkinsonism was expected to be higher in our study population, even after shifting to SGA. The second is that Asian or Chinese populations might be more vulnerable to EPS side effects than Caucasian populations (Lane, et al., 1995; Lin, et al., 1988; Frackiewicz, et al., 1997) .
The olanzapine group showed a lower incidence of clinically significant acute dystonia or parkinsonism requiring management by anticholinergic drugs, and the improvement in psychotic symptoms was similar to that of the risperidone group. The results of our study favour olanzapine as a better choice in schizophrenic patients with severe FGA-induced acute dystonia or parkinsonism side effects. Our results are compatible with the Maudsley prescribing guidelines, which suggest quetiapine, olanzapine or clozapine as first choice drugs for EPS-sensitive psychotic patients, and risperidone, sertindole, ziprasidone, aripiprazole as second choice alternatives (Taylor, et al., 2003) .
There were some limitations in our study. First, we did not have a FGA or placebo control group because of ethical concerns. Hence, this study might have a placebo effect and overestimated the effects of SGA on improving FGA-induced EPS. Second, our study was a rater-blinded study and might have measurement bias because of the influence of unblinding primary care physicians and patients. Third, our study was a flexible dose study; hence, we do not know the exact effect of some fixed dose of risperidone and olanzapine. We cannot totally rule out the possibility that inappropriate dose titration occurred in some patients. Finally, our study did not perform a laboratory assessment; hence, we could not assess the patient's blood sugar, triglyceride, prolactin and other biochemistry data.
In summary, although our study had the above limitations, the results still have important clinical implications for clinicians treating patients with FGA-induced severe acute dystonia or parkinsonism side effects. We hope that there will be more related studies focusing on EPS-sensitive populations, especially Chinese or Asian groups, to help clinicians make appropriate clinical decisions.
